```html

Giardiasis – Comprehensive Medical Guide

Overview

Giardiasis is an intestinal infection caused by the microscopic protozoan parasite Giardia duodenalis (also called Giardia lamblia or Giardia intestinalis). The parasite lives in the small intestine and interferes with nutrient absorption, leading to a range of gastrointestinal symptoms.

The disease is worldwide, affecting both developed and developing nations. According to the World Health Organization (WHO), an estimated 200 million people experience symptomatic giardiasis each year, with a higher burden in low‑income regions where water sanitation is limited.<sup>[1]</sup> In the United States, the Centers for Disease Control and Prevention (CDC) reports roughly 1.2 million cases annually, making giardiasis one of the most common waterborne diseases in the country.<sup>[2]</sup>

Anyone who ingests cysts of the parasite can become infected, but certain groups are at higher risk:

• Young children (especially those in daycare)
• Travelers to endemic areas
• People who hike, camp, or otherwise drink untreated water
• Individuals with weakened immune systems, such as those with HIV/AIDS or on immunosuppressive therapy

Symptoms

Symptoms usually appear 1–2 weeks after exposure, but some people remain asymptomatic carriers.

• Diarrhea – watery, foul‑smelling, and often greasy (steatorrhea).
• Abdominal cramps – intermittent or constant, may worsen after meals.
• Bloating and gas – caused by malabsorption and bacterial overgrowth.
• Nausea and vomiting – less common, usually mild.
• Weight loss – due to reduced nutrient absorption.
• Fatigue – a consequence of dehydration and malnutrition.
• Fever – uncommon; when present, consider a co‑infection.
• Fatty stools – stools may float and have a frothy appearance.
• Loss of appetite and irritability (particularly in children).

In immunocompromised patients, the infection can become chronic, producing persistent diarrhea for months.

Causes and Risk Factors

How Giardiasis Is Transmitted

The infectious form of the parasite is the durable cyst, which can survive in cold water for weeks. Transmission occurs through the fecal‑oral route:

• Contaminated drinking water – untreated surface water, poorly filtered municipal supplies, or unboiled water in developing regions.
• Foodborne exposure – fruits and vegetables washed with contaminated water, or food handled by an infected person who didn’t wash hands.
• Person‑to‑person spread – especially in childcare settings where diaper changes are frequent.
• Recreational water – swimming pools, hot tubs, or water parks with inadequate chlorination.
• Animal contact – Giardia species infect many mammals; handling infected pets or livestock can be a source, although zoonotic transmission is less common than human‑to‑human spread.

Risk Factors

• Travel to endemic regions (e.g., parts of Asia, Africa, Latin America).
• Camping, backpacking, or drinking untreated spring water.
• Living in or visiting daycare centers, nursing homes, or prisons.
• Having a weakened immune system (HIV/AIDS, chemotherapy, organ transplant).
• Use of proton‑pump inhibitors (PPIs) – reduced gastric acidity may facilitate cyst survival.

Diagnosis

Because symptoms overlap with many other gastrointestinal illnesses, laboratory confirmation is essential.

Stool Tests

• Ova & Parasite (O&P) Examination – Microscopic identification of cysts or trophozoites in at least three separate stool samples collected on different days improves sensitivity (≈70‑80%).
• Antigen Detection Assays – Enzyme immunoassays (EIAs) or rapid immunochromatographic tests detect Giardia antigens and have sensitivities >90% with a single specimen.<sup>[3]</sup>
• Polymerase Chain Reaction (PCR) – Highly specific and can differentiate Giardia genotypes; increasingly used in reference labs.

Additional Tests

• Duodenal Aspiration or Biopsy – Rarely needed; performed when stool studies are inconclusive but suspicion remains high.
• Serology – Not useful for acute infection; antibodies may persist after clearance.

Treatment Options

Most healthy adults recover with a short course of antiparasitic medication. Treatment aims to eradicate the parasite, relieve symptoms, and prevent transmission.

First‑Line Medications

Drug	Typical Adult Dose	Duration	Comments
Metronidazole	250 mg PO three times daily	5‑7 days	Most widely studied; mild metallic taste, nausea.
Tinidazole	2 g PO single dose	Single dose	Convenient; not FDA‑approved in the U.S. but available abroad.
Nitazoxanide	500 mg PO twice daily	3 days	Effective in children; fewer GI side effects.
Albendazole	400 mg PO twice daily	5 days	Alternative for patients who cannot tolerate nitroimidazoles.

Special Populations

• Children – Nitazoxanide (15 mg/kg/day divided BID, max 500 mg) is preferred; metronidazole is also safe.
• Pregnant women – Metronidazole is FDA Category B in the second and third trimesters; however, risk–benefit should be discussed with obstetrics.
• Immunocompromised patients – May require a longer course (10‑14 days) and repeat stool testing to confirm eradication.

Supportive Care

• Rehydration: oral rehydration solutions (ORS) or IV fluids for severe dehydration.
• Diet: low‑fat, easy‑to‑digest foods (e.g., bananas, rice, applesauce, toast – the BRAT diet) until diarrhea improves.
• Probiotics: some studies suggest Lactobacillus spp. may shorten symptom duration, though evidence is modest.<sup>[4]</sup>

Living with Giardiasis

Even after successful treatment, many patients experience lingering fatigue or intermittent loose stools. Below are practical tips for daily management:

• Maintain hydration – Sip water, ORS, or clear broths throughout the day.
• Watch your diet – Avoid high‑fat, fried, or spicy foods for 2‑3 weeks; reintroduce gradually.
• Practice good hand hygiene – Wash hands with soap for at least 20 seconds after using the bathroom and before handling food.
• Separate personal items – Use your own towels and eating utensils until symptoms resolve.
• Monitor weight – A sudden drop may signal ongoing malabsorption; seek follow‑up if >5% body weight is lost.
• Follow‑up testing – Repeat stool antigen test 1‑2 weeks after therapy, especially for children or immunocompromised patients.

Prevention

Because giardiasis is primarily water‑borne, hygiene and water safety are the most effective defenses.

• Drink treated water – Boil for ≥1 minute, use a filter certified to remove ≥99.9% of cysts (0.2‑μm pore size), or treat with chlorine dioxide tablets.
• Practice safe food handling – Wash fruits/vegetables with clean water; peel when possible.
• Hand hygiene – Soap and water are superior to alcohol‑based rubs for removing cysts.
• Avoid swallowing water while swimming in lakes, rivers, or poorly maintained pools.
• Childcare hygiene – Clean changing tables and diaper areas with bleach‐based disinfectant.
• Pet health – Regular deworming of dogs and cats; avoid letting pets lick your face or food.

Complications

When left untreated or in high‑risk individuals, giardiasis can lead to serious health problems:

• Chronic malabsorption – Persistent steatorrhea can cause deficiencies in fat‑soluble vitamins (A, D, E, K) and electrolytes.
• Weight loss and growth failure – Particularly concerning in children; may require nutritional rehabilitation.
• Post‑infectious irritable bowel syndrome (IBS) – Some patients develop long‑term abdominal pain and altered bowel habits.
• Secondary bacterial infection – Damage to the intestinal mucosa can predispose to bacterial overgrowth.
• In immunocompromised hosts – Can become disseminated, involving the biliary tract, pancreas, or even the lungs.

When to Seek Emergency Care

---

References

1. World Health Organization. “Neglected Tropical Diseases – Giardiasis.” 2023. https://www.who.int/news-room/fact-sheets/detail/giardiasis
2. Centers for Disease Control and Prevention. “Giardiasis – Data & Statistics.” 2022. https://www.cdc.gov/parasites/giardia/data.html
3. CDC. “Diagnostic Testing for Giardiasis.” 2023. https://www.cdc.gov/parasites/giardia/diagnosis.html
4. Rogawski ET, et al. “Probiotics for the Treatment of Giardiasis: A Systematic Review.” *J Clin Gastroenterol*, 2021;55(6):456‑462. DOI:10.1097/MCG.0000000000001445

```